Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses

Jeffrey L. Lennox, Edwin DeJesus, Daniel S. Berger, Adriano Lazzarin, Richard B Pollard, Jose Valdez Ramalho Madruga, Jing Zhao, Hong Wan, Christopher L. Gilbert, Hedy Teppler, Anthony J. Rodgers, Richard J O Barnard, Michael D. Miller, Mark J. DiNubile, Bach Yen Nguyen, Randi Leavitt, Peter Sklar

Research output: Contribution to journalArticle

198 Citations (Scopus)

Abstract

Background: We analyzed the 96-week results in the overall population and in prespecified subgroups from the ongoing STARTMRK study of treatment-naive HIV-infected patients. Methods: Eligible patients with HIV-1 RNA (vRNA) levels >5000 copies per milliliter and without baseline resistance to efavirenz, tenofovir, or emtricitabine were randomized in a double-blind noninferiority study to receive raltegravir or efavirenz, each combined with tenofovir/emtricitabine. Results: At week 96 counting noncompleters as failures, 81% versus 79% achieved vRNA levels <50 copies per milliliter in the raltegravir and efavirenz groups, respectively [δ (95% confidence interval) = 2% (24 to 9), noninferiority P < 0.001]. Mean change in baseline CD4 count was 240 and 225 cells per cubic millimeter in the raltegravir and efavirenz groups, respectively [δ (95% confidence interval) = 15 (-13 to 42)]. Treatment effects were consistent across prespecified baseline demographic and prognostic subgroups. Fewer drug-related clinical adverse events (47% versus 78%; P < 0.001) occurred in raltegravir than efavirenz recipients. Both regimens had modest effects on serum lipids and glucose levels and on body fat composition. Conclusions: When combined with tenofovir/emtricitabine in treatment-naive patients, raltegravir exhibited durable antiretroviral activity that was noninferior to the efficacy of efavirenz through 96 weeks of therapy. Subgroup analyses were generally consistent with the overall findings. Both regimens were well tolerated.

Original languageEnglish (US)
Pages (from-to)39-48
Number of pages10
JournalJournal of Acquired Immune Deficiency Syndromes
Volume55
Issue number1
DOIs
StatePublished - Sep 1 2010

Fingerprint

efavirenz
Tenofovir
HIV-1
Safety
Therapeutics
Confidence Intervals
CD4 Lymphocyte Count
Body Composition
Double-Blind Method
Raltegravir Potassium
Adipose Tissue
Demography
HIV
RNA

Keywords

  • Efavirenz
  • Integrase inhibitor
  • MK-0518
  • Raltegravir
  • STARTMRK
  • Treatment-naive patients

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients : 96-week efficacy, durability, subgroup, safety, and metabolic analyses. / Lennox, Jeffrey L.; DeJesus, Edwin; Berger, Daniel S.; Lazzarin, Adriano; Pollard, Richard B; Madruga, Jose Valdez Ramalho; Zhao, Jing; Wan, Hong; Gilbert, Christopher L.; Teppler, Hedy; Rodgers, Anthony J.; Barnard, Richard J O; Miller, Michael D.; DiNubile, Mark J.; Nguyen, Bach Yen; Leavitt, Randi; Sklar, Peter.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 55, No. 1, 01.09.2010, p. 39-48.

Research output: Contribution to journalArticle

Lennox, JL, DeJesus, E, Berger, DS, Lazzarin, A, Pollard, RB, Madruga, JVR, Zhao, J, Wan, H, Gilbert, CL, Teppler, H, Rodgers, AJ, Barnard, RJO, Miller, MD, DiNubile, MJ, Nguyen, BY, Leavitt, R & Sklar, P 2010, 'Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses', Journal of Acquired Immune Deficiency Syndromes, vol. 55, no. 1, pp. 39-48. https://doi.org/10.1097/QAI.0b013e3181da1287
Lennox, Jeffrey L. ; DeJesus, Edwin ; Berger, Daniel S. ; Lazzarin, Adriano ; Pollard, Richard B ; Madruga, Jose Valdez Ramalho ; Zhao, Jing ; Wan, Hong ; Gilbert, Christopher L. ; Teppler, Hedy ; Rodgers, Anthony J. ; Barnard, Richard J O ; Miller, Michael D. ; DiNubile, Mark J. ; Nguyen, Bach Yen ; Leavitt, Randi ; Sklar, Peter. / Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients : 96-week efficacy, durability, subgroup, safety, and metabolic analyses. In: Journal of Acquired Immune Deficiency Syndromes. 2010 ; Vol. 55, No. 1. pp. 39-48.
@article{9177977170124d7d8f1a018156ae3f61,
title = "Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses",
abstract = "Background: We analyzed the 96-week results in the overall population and in prespecified subgroups from the ongoing STARTMRK study of treatment-naive HIV-infected patients. Methods: Eligible patients with HIV-1 RNA (vRNA) levels >5000 copies per milliliter and without baseline resistance to efavirenz, tenofovir, or emtricitabine were randomized in a double-blind noninferiority study to receive raltegravir or efavirenz, each combined with tenofovir/emtricitabine. Results: At week 96 counting noncompleters as failures, 81{\%} versus 79{\%} achieved vRNA levels <50 copies per milliliter in the raltegravir and efavirenz groups, respectively [δ (95{\%} confidence interval) = 2{\%} (24 to 9), noninferiority P < 0.001]. Mean change in baseline CD4 count was 240 and 225 cells per cubic millimeter in the raltegravir and efavirenz groups, respectively [δ (95{\%} confidence interval) = 15 (-13 to 42)]. Treatment effects were consistent across prespecified baseline demographic and prognostic subgroups. Fewer drug-related clinical adverse events (47{\%} versus 78{\%}; P < 0.001) occurred in raltegravir than efavirenz recipients. Both regimens had modest effects on serum lipids and glucose levels and on body fat composition. Conclusions: When combined with tenofovir/emtricitabine in treatment-naive patients, raltegravir exhibited durable antiretroviral activity that was noninferior to the efficacy of efavirenz through 96 weeks of therapy. Subgroup analyses were generally consistent with the overall findings. Both regimens were well tolerated.",
keywords = "Efavirenz, Integrase inhibitor, MK-0518, Raltegravir, STARTMRK, Treatment-naive patients",
author = "Lennox, {Jeffrey L.} and Edwin DeJesus and Berger, {Daniel S.} and Adriano Lazzarin and Pollard, {Richard B} and Madruga, {Jose Valdez Ramalho} and Jing Zhao and Hong Wan and Gilbert, {Christopher L.} and Hedy Teppler and Rodgers, {Anthony J.} and Barnard, {Richard J O} and Miller, {Michael D.} and DiNubile, {Mark J.} and Nguyen, {Bach Yen} and Randi Leavitt and Peter Sklar",
year = "2010",
month = "9",
day = "1",
doi = "10.1097/QAI.0b013e3181da1287",
language = "English (US)",
volume = "55",
pages = "39--48",
journal = "Journal of acquired immune deficiency syndromes (1999)",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients

T2 - 96-week efficacy, durability, subgroup, safety, and metabolic analyses

AU - Lennox, Jeffrey L.

AU - DeJesus, Edwin

AU - Berger, Daniel S.

AU - Lazzarin, Adriano

AU - Pollard, Richard B

AU - Madruga, Jose Valdez Ramalho

AU - Zhao, Jing

AU - Wan, Hong

AU - Gilbert, Christopher L.

AU - Teppler, Hedy

AU - Rodgers, Anthony J.

AU - Barnard, Richard J O

AU - Miller, Michael D.

AU - DiNubile, Mark J.

AU - Nguyen, Bach Yen

AU - Leavitt, Randi

AU - Sklar, Peter

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Background: We analyzed the 96-week results in the overall population and in prespecified subgroups from the ongoing STARTMRK study of treatment-naive HIV-infected patients. Methods: Eligible patients with HIV-1 RNA (vRNA) levels >5000 copies per milliliter and without baseline resistance to efavirenz, tenofovir, or emtricitabine were randomized in a double-blind noninferiority study to receive raltegravir or efavirenz, each combined with tenofovir/emtricitabine. Results: At week 96 counting noncompleters as failures, 81% versus 79% achieved vRNA levels <50 copies per milliliter in the raltegravir and efavirenz groups, respectively [δ (95% confidence interval) = 2% (24 to 9), noninferiority P < 0.001]. Mean change in baseline CD4 count was 240 and 225 cells per cubic millimeter in the raltegravir and efavirenz groups, respectively [δ (95% confidence interval) = 15 (-13 to 42)]. Treatment effects were consistent across prespecified baseline demographic and prognostic subgroups. Fewer drug-related clinical adverse events (47% versus 78%; P < 0.001) occurred in raltegravir than efavirenz recipients. Both regimens had modest effects on serum lipids and glucose levels and on body fat composition. Conclusions: When combined with tenofovir/emtricitabine in treatment-naive patients, raltegravir exhibited durable antiretroviral activity that was noninferior to the efficacy of efavirenz through 96 weeks of therapy. Subgroup analyses were generally consistent with the overall findings. Both regimens were well tolerated.

AB - Background: We analyzed the 96-week results in the overall population and in prespecified subgroups from the ongoing STARTMRK study of treatment-naive HIV-infected patients. Methods: Eligible patients with HIV-1 RNA (vRNA) levels >5000 copies per milliliter and without baseline resistance to efavirenz, tenofovir, or emtricitabine were randomized in a double-blind noninferiority study to receive raltegravir or efavirenz, each combined with tenofovir/emtricitabine. Results: At week 96 counting noncompleters as failures, 81% versus 79% achieved vRNA levels <50 copies per milliliter in the raltegravir and efavirenz groups, respectively [δ (95% confidence interval) = 2% (24 to 9), noninferiority P < 0.001]. Mean change in baseline CD4 count was 240 and 225 cells per cubic millimeter in the raltegravir and efavirenz groups, respectively [δ (95% confidence interval) = 15 (-13 to 42)]. Treatment effects were consistent across prespecified baseline demographic and prognostic subgroups. Fewer drug-related clinical adverse events (47% versus 78%; P < 0.001) occurred in raltegravir than efavirenz recipients. Both regimens had modest effects on serum lipids and glucose levels and on body fat composition. Conclusions: When combined with tenofovir/emtricitabine in treatment-naive patients, raltegravir exhibited durable antiretroviral activity that was noninferior to the efficacy of efavirenz through 96 weeks of therapy. Subgroup analyses were generally consistent with the overall findings. Both regimens were well tolerated.

KW - Efavirenz

KW - Integrase inhibitor

KW - MK-0518

KW - Raltegravir

KW - STARTMRK

KW - Treatment-naive patients

UR - http://www.scopus.com/inward/record.url?scp=77956646683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956646683&partnerID=8YFLogxK

U2 - 10.1097/QAI.0b013e3181da1287

DO - 10.1097/QAI.0b013e3181da1287

M3 - Article

C2 - 20404738

AN - SCOPUS:77956646683

VL - 55

SP - 39

EP - 48

JO - Journal of acquired immune deficiency syndromes (1999)

JF - Journal of acquired immune deficiency syndromes (1999)

SN - 1525-4135

IS - 1

ER -